Results 131 to 140 of about 9,130 (237)

Low‐Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire

open access: yesJournal of Viral Hepatitis, Volume 33, Issue 6, June 2026.
ABSTRACT Achieving hepatitis C virus (HCV) elimination requires innovative paradigms that overcome barriers to treatment, such as requiring pre‐treatment elastography or phlebotomy‐based fibrosis assessment. To identify patients at low risk of advanced fibrosis or decompensated cirrhosis within our HCV treatment programme, we developed and ...
Hunter Spencer   +4 more
wiley   +1 more source

Serum microRNA-122 predicts survival in patients with liver cirrhosis

open access: yes, 2012
Background: Liver cirrhosis is associated with high morbidity and mortality. MicroRNAs (miRs) circulating in the blood are an emerging new class of biomarkers.
Stefan Zeuzem   +17 more
core   +1 more source

Resolved HBV Infection Is Not Associated With Liver‐Related Outcomes in Survival Analysis of Caucasians After HCV Cure

open access: yesLiver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Previous exposure to hepatitis B virus (HBV) may influence the risk of developing hepatocellular carcinoma (HCC) and other liver‐related events (LRE), in particular in patients after HCV cure. Previous studies were not conclusive and there are only few large studies on this topic from Europe. Methods We analysed clinical endpoints (≥
Laura Muana Wilhelm   +10 more
wiley   +1 more source

Effects of Opioids, Benzodiazepines, Gabapentinoids, and Antidepressants on Fracture Risk in Alcohol‐Related Cirrhosis

open access: yesLiver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background Patients with alcohol‐related liver cirrhosis (ALD cirrhosis) have an increased risk of falls and fractures. Opioids, benzodiazepines, gabapentinoids, and antidepressants are known to increase fall risk. Aims We aimed to determine the effects of opioids, benzodiazepines, gabapentinoids, and antidepressants on fracture risk in ALD ...
Frederik Kraglund   +4 more
wiley   +1 more source

Real‐World Outcomes of Opti‐Hep‐D: An Innovative, Multicentre and Multidisciplinary Program Improving Hepatitis D Cascade of Care

open access: yesLiver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aim Hepatitis D virus (HDV) infection remains underdiagnosed, and real‐world data on screening and linkage to care are limited. We assessed the implementation of Opti‐Hep‐D, a publicly funded initiative for HDV management in the Spanish region of Catalonia.
Adriana Palom   +20 more
wiley   +1 more source

The Link of Portal‐Hypertensive Gastropathy to Anaemia, Systemic Inflammation and Disease Progression in Cirrhosis

open access: yesLiver International, Volume 46, Issue 6, June 2026.
ABSTRACT Background and Aims Portal‐hypertensive gastropathy (PHG) is considered a potential cause of chronic bleeding and anaemia in patients with advanced chronic liver disease (ACLD) and might represent an endoscopic reflection of an impaired gut‐liver axis associated with portal hypertension.
Nikolaus Pfisterer   +16 more
wiley   +1 more source

Distal splenorenal shunt: Preferred treatment for recurrent variceal hemorrhage in the patient with well-compensated cirrhosis

open access: yes
Hypothesis: Distal splenorenal shunt (DSRS) is a safe and effective treatment for patients with Child-Pugh class A and B cirrhosis with recurrent variceal hemorrhage after failed transjugular intrahepatic portosystemic shunt.
-
core  

Prophylaxis of first variceal hemorrhage in patients with liver cirrhosis [PDF]

open access: yes, 1986
Paumgartner, Gustav   +3 more
core  

MELD, MELD 3.0, versus Child score to predict mortality after acute variceal hemorrhage: A multicenter US cohort. [PDF]

open access: yesHepatol Commun, 2023
Buckholz A   +7 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy